Characteristic; indication | Group; mean ± SD* | p value | |
---|---|---|---|
PRA | TLA | ||
No. of doses of narcotic, median (IQR) | |||
All tumour types | 2.5 (1.0–4.8) | 3.0 (1.0–7.0) | 0.07§ |
Excluding pheochromocytoma | 2.5 (1.0–4.0) | 4.0 (2.0–6.5) | 0.07§ |
Pheochromocytoma | 3.5 (1.0–7.5) | 2.5 (1.0–7.5) | 0.8§ |
Primary aldosteronism | 2.5 (1.0–4.2) | 4.0 (2.0–5.0) | 0.4§ |
Cushing syndrome | 1.5 (0.0–4.0) | 35.0 (17.5–38) | 0.2§ |
Nonfunctional | 2.0 (0.0–4.5) | 2.0 (2.0–6.5) | 0.3§ |
Anesthesia time, min† | |||
All tumour types | 51.5 ± 11.5 | 63.7 ± 17.3 | < 0.001¶ |
Excluding pheochromocytoma | 50.4 ± 10.6 | 54.8 ± 10.3 | 0.07¶ |
Pheochromocytoma | 61.3 ± 15.2 | 75.0 ± 17.9 | 0.01 |
Primary aldosteronism | 49.8 ± 8.3 | 57.1 ± 11.3 | 0.1 |
Cushing syndrome | 58.5 ± 16.4 | 52.0 ± 5.6 | 0.4¶ |
Nonfunctional | 45.2 ± 9.3 | 53.6 ± 10.9 | 0.09 |
Operative time, min‡ | |||
All tumour types | 77.9 ± 40.4 | 118.4 ± 47.4 | < 0.001¶ |
Excluding pheochromocytoma | 79.5 ± 41.6 | 105.4 ± 22.3 | < 0.001¶ |
Pheochromocytoma | 64.2 ± 26.9 | 135.1 ± 64.1 | 0.005¶ |
Primary aldosteronism | 77.7 ± 44.9 | 103.7 ± 21.1 | 0.001¶ |
Cushing syndrome | 67.0 ± 18.0 | 93.7 ± 12.5 | 0.04 |
Nonfunctional | 99.9 ± 39.0 | 110.0 ± 25.3 | 0.5 |
Length of stay, median (IQR), d | |||
All tumour types | 2.0 (2.0–3.0) | 4.0 (3.0–5.0) | < 0.001§ |
Excluding pheochromocytoma | 2.0 (2.0–3.0) | 3.0 (2.0–3.5) | 0.01§ |
Pheochromocytoma | 2.0 (2.0–2.8) | 5.0 (4.0–5.8) | < 0.001¶ |
Primary aldosteronism | 2.0 (2.0–3.0) | 3.0 (2.0–3.0) | 0.08§ |
Cushing syndrome | 4.0 (3.0–5.0) | 7.0 (5.0–7.0) | 0.3 |
Nonfunctional | 2.0 (1.0–2.0) | 2.0 (2.0–3.0) | 0.009§ |
IQR = interquartile range; PRA = posterior retroperitoneoscopic adrenalectomy; SD = standard deviation; TLA = transperitoneal laparoscopic adrenalectomy.
↵* Except where noted otherwise.
↵† Time from patient entry into the operating room to initial incision.
↵‡ Time from initial incision to completion of skin closure.
↵§ Wilcoxon rank-sum test.
↵¶ t test.